Clinical trial
The Use of GFAP and UCH-L1 Biomarkers in Clinical Practice for the Management of Mild Traumatic Brain Injury
NCT07931066 is registered in ClinicalTrials.gov with University Hospital, Grenoble as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Use of GFAP and UCH-L1 Biomarkers in Clinical Practice for the Management of Mild Traumatic Brain Injury
- Lead sponsor
- University Hospital, Grenoble
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 5, 2026
- Completion date
- July 30, 2027
- Enrollment
- 800 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
biomarkers, mild traumatic brain injury (mtbi)
Arms
As registered; 1 arm.
-
All adult patients admitted in the Emergency Department for mild traumatic brain injury
All adult patients presenting to the Grenoble Alpes University Hospital emergency department for mild traumatic brain injury will be enrolled and analyzed during the study period
Primary endpoints
Registered primary outcome measures; 1 primary.
-
The proportion of patients who underwent GFAP and UCH-L1 testing, and in whom a brain CT scan was avoided following a negative result in accordance with current guidelines
The proportion of patients who underwent GFAP and UCH-L1 testing, and in whom a brain CT scan was avoided following a negative result in accordance with current guidelines
Lead sponsor's other trials
University Hospital, Grenoble, most recent start first.
+832 more trials See the organization page
Similar trials
Same condition (Brain Concussion) and phase, most recent start first.
+167 more trials See the condition page